FATE - Fate Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

11.49

-0.07 (-0.61%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	11.56
Open	11.56
Bid	10.12 x 1100
Ask	11.70 x 900
Day's Range	11.13 - 11.59
52 Week Range	2.52 - 14.45
Volume	232,159
Avg. Volume	670,593

Market Cap	607.343M
Beta	2.63
PE Ratio (TTM)	N/A
EPS (TTM)	-1.02
Earnings Date	Aug 13, 2018 - Aug 17, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	17.80

Trade prices are not sourced from all markets

All

News

Press Releases

GlobeNewswire4 days ago
Analysis: Positioning to Benefit within Beazer Homes, Tejon Ranch, Ladder Capital, Fate Therapeutics, Benefitfocus, and H&E Equipment Services — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, May 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Beazer ...
GlobeNewswire10 days ago
Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today the Company has gained access to additional intellectual property from Memorial Sloan Kettering Cancer Center (MSK) that enables the development of gene-edited T-cell immunotherapies. The newly-licensed portfolio of intellectual property covers new chimeric antigen receptor (CAR) constructs as well as off-the-shelf CAR T cells, including the use of CRISPR and other innovative technologies for their production. Fate Therapeutics is utilizing gene editing under its ongoing collaboration for the research and development of off-the-shelf CAR T-cell immunotherapies with Michel Sadelain, M.D., Ph.D., Director of the Center for Cell Engineering and the Stephen and Barbara Friedman Chair at MSK.
Thomson Reuters StreetEvents15 days ago
Edited Transcript of FATE earnings conference call or presentation 10-May-18 9:00pm GMT
Q1 2018 Fate Therapeutics Inc Earnings Call
Associated Press16 days ago
Fate Therapeutics: 1Q Earnings Snapshot
The San Diego-based company said it had a loss of 27 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
GlobeNewswire16 days ago
Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress
No Cancer Relapse Reported in Phase 1 PROTECT Study of ProTmune. Anti-tumor Activity with No Dose-limiting Toxicities Observed in Initial Phase 1 Dose Escalation of FATE-NK100 in Advanced Solid and Liquid ...
GlobeNewswire23 days ago
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results
SAN DIEGO, May 03, 2018-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...
GlobeNewswire24 days ago
Fate Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference
SAN DIEGO, May 02, 2018-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...
GlobeNewswirelast month
Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Program
Off-the-Shelf CAR T-cell Product Candidate Designed to Target CD19-positive Tumor Cells and to Overcome Antigen Escape. Manufacture from Master iPSC Line Enables Mass Production and Broad Accessibility ...
Simply Wall St.2 months ago
Fate Therapeutics Inc’s (NASDAQ:FATE) Shift From Loss To Profit
Fate Therapeutics Inc’s (NASDAQ:FATE): Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The US$489.72M market-cap company announced a latest loss ofRead More...
ACCESSWIRE2 months ago
Wired News - Fate Therapeutics Presented Positive Clinical Data of FATE-NK100's APOLLO Phase-1 Study in Recurrent Ovarian Cancer at the Innate Killer Summit 2018
Stock Monitor: Aeterna Zentaris Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 3, 2018 / Active-Investors.com has just released a free research report on Fate Therapeutics, Inc. (NASDAQ: FATE ...
Thomson Reuters StreetEvents2 months ago
Edited Transcript of FATE earnings conference call or presentation 1-Nov-17 9:00pm GMT
Q3 2017 Fate Therapeutics Inc Earnings Call
GlobeNewswire2 months ago
Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018
SAN DIEGO, March 29, 2018-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...
GlobeNewswire2 months ago
Recent Analysis Shows EPAM, Sibanye Gold, Fate Therapeutics, Howard Hughes, CBL & Associates Properties, and Quorum Health Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
GlobeNewswire2 months ago
Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune™
No Events of Cancer Relapse. No ProTmune-related Serious Adverse Events Reported by Investigators. SAN DIEGO, March 19, 2018-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated ...
ACCESSWIRE2 months ago
Wired News – CTI BioPharma’s Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA Oncology
Stock Monitor: Fate Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 13, 2018 / Active-Investors.com has just released a free research report on CTI BioPharma Corp. (NASDAQ: CTIC ). ...
Associated Press3 months ago
Fate Therapeutics reports 4Q loss
On a per-share basis, the San Diego-based company said it had a loss of 29 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
GlobeNewswire3 months ago
Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress
Initial Clinical Data of FATE-NK100 in Relapsed/ Refractory AML Show Rapid Reduction of Leukemic Blasts in the Bone Marrow. All Subjects in PROTECT Phase 1 Study of ProTmune Achieve Day 100 Relapse-free ...
GlobeNewswire3 months ago
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO, Feb. 27, 2018-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...
Motley Fool3 months ago
3 Biotech Stocks That Soared This Week: Are They Buys?
Can the momentum continue for these hot biotech stocks?
Simply Wall St.4 months ago
With A -16.46% Earnings Drop, Is Fate Therapeutics Inc’s (NASDAQ:FATE) Performance A Concern?
Examining Fate Therapeutics Inc’s (NASDAQ:FATE) past track record of performance is a useful exercise for investors. It allows us to reflect on whether the company has met or exceed expectations,Read More...
Motley Fool4 months ago
Here's Why Fate Therapeutics Rose as Much as 18% Today
Make that two consecutive days of riding the momentum from the Juno Therapeutics acquisition.